Pitch & Partner

30 March -1 April 2020 | Business Design Centre London

 

 

2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams

 

 

Pitch & Partner

PITCH AND PARTNER, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

08:45

Welcome – Jessica Robinson, Project Director, Advanced Therapies 2020, Terrapinn

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
Bradley Campbell
10:00

Importance of patient focus in developing gene therapy for rare diseases

10:20

Morning Coffee Break

Martin Pule
11:20

Keynote presentation: War in the Blood - the latest in the front line of CAR-T clinical research

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

10. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, BOKU

3. Ensuring safe delivery to patients and fast time-to-market of advanced therapies - How to address challenges of drug administration, fill & finish, packaging & stability?
Diana Lober

Diana Lober, Product Manager, Schott AG

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

7. Reserved for Fujifilm Diosynth Biotechnology
13:00

Lunch

PITCH AND PARTNER

Investor Forum & company pitches

Panel discussion
Panel discussion
PITCH AND PARTNER
15:00

Multi-perspective discussion: How to partner with public/private organizations

  • How to approach big pharma/government organisations for support
  • How can companies correctly identify a fit and interest?
  • Can partnering prevent biotech start-ups from getting stuck before Ph1?
  • Do and don’ts with partnerships
David Mazzo
PITCH AND PARTNER
15:40

Advancing restorative therapies to treat ischemic disease

Stuart Collinson
PITCH AND PARTNER
15:50

Regenerative medicine – a small molecule approach

Abdulkader Rahmo
PITCH AND PARTNER
16:00

Advanced therapy using a stem cell derived extracellular matrix

16:20

Afternoon Break

Timothy Davies
PITCH AND PARTNER
17:00

Why Specialised Logistics

Timothy Davies, Business Development Manager, A4P Bio
Christina O'Neill
PITCH AND PARTNER
17:10

Angicyte, a unique cell therapy for blood vessel regeneration

  • There is an urgent need for new therapies for wound healing.
  • VascVersa’s vision is to create the next generation of living advanced therapies using Angicyte.
  • Angicyte cell therapy creates new blood vessels to improve blood supply and promote healing.
Agnieszka Janeczek
PITCH AND PARTNER
17:20

Renovite™ - synthetic nanoclay gels as a platform for regenerative medicine

John Sinden
PITCH AND PARTNER
17:30

Glialign’s Engineered Neural Tissue (EngNT), an advanced therapy solution for peripheral nerve repair

Elzbieta Maria Piatkowska
PITCH AND PARTNER
17:40

The role of AI in development of immunotherapies: opportunities and challenges

  • Biological drug development: a niche waiting to be explored
  • AI in prediction of side effect of immunotherapies
  • Immunotherapy as a tool for precision medicine
Juergen Weisser
PITCH AND PARTNER
17:50

Title TBC (PITCH AND PARTNER)

Juergen Weisser, Chief Executive Officer, RheinCell Therapeutics
18:00

Close of Conference for the day - Please join us for an evening drinks reception

last published: 05/Mar/20 17:05

PITCH AND PARTNER, Wednesday 1 April 2020

CONFERENCE DAY 1 - WEDNESDAY 1st April 2020

Opening Keynotes Day 2 — The latest science in gene therapy and gene editing

Federico Mingozzi
09:00

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner
09:20

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau
10:00

In vivo gene editing paediatric patients with rare diseases

10:20

Networking Refreshments

PITCH AND PARTNER

Leo Groenewegen
PITCH AND PARTNER
11:30

Bringing continuous production to cell manufacturing

  • Batch VS continous cell production
  • Overcoming scaling issues
  • Serum free production
Leo Groenewegen, Chief Executive Officer, CellulaRevolution
Peter Hamley
PITCH AND PARTNER
11:40

Samsara Therapeutics - Targeting the biology of Ageing

Aline Miller
PITCH AND PARTNER
11:50

Self-Assembling Peptide Hydrogels for regenerative medicine; from bench to bedside

Brad Hamilton
PITCH AND PARTNER
12:00

GoodCell: The Impact of Personal Biobanking on Therapeutic Development

Orion P Keifer
PITCH AND PARTNER
12:10

Tunable Gene Therapy for Neurological Disease

Sebastien Walpen
PITCH AND PARTNER
12:20

Toward an automated cell culture monitoring

Mangala Srinivas
PITCH AND PARTNER
12:30

Non-invasive, quantitative imaging of cell therapies in humans for biodistribution and pharmacokinetics

Nicolas Rousseau
PITCH AND PARTNER
12:40

EVerZom: a large scale bioproduction platform of extracellular vesicles

  • Game changing technology to produce EV at large scale
  • Caracterisation of EVs produced with this new technology
  • Applications in fistula and cardiac repair
Victor R De La Rosa
PITCH AND PARTNER
12:50

Ultroxa® Polymer platform for advanced drug and gene delivery

  • Poly(2-oxazoline)s (PAOx, POZ) as versatile polymer platform for sustained and targeted drug delivery
  • Ultroxa® technology and unique ability to design and produce ultra-defined polymers for pharma and biotech
  • Ultroxa® Polyethyleneimines (PEI) and new superior polymer vectors for transfection
Victor R De La Rosa, Chief Scientific Officer, Avroxa bvba - Ultroxa Polymers
13:00

Neworking Lunch

PITCH & PARTNER

Thomas Mørch Frøsig
PITCH AND PARTNER
14:20

Accelerating drug development by immune monitoring

Our vision is to decrease the risk of drug development failure by:
  • Maximizing the mechanistic information obtained from all phases of drug development
  • Identifying customer needs and tailoring the solutions delivered accordingly
  • Giving access to frontline expertise as part of our service
Thomas Mørch Frøsig, Chief Executive Officer, ImmuMap
Chiara Gai
PITCH AND PARTNER
14:30

Innovative plant-based solution for chronic wound care

  • EvoBiotech discovered an innovative plant-derived active ingredient which promote regeneration of skin and blood vessel.
  • The active ingredient can be incorporated into an advanced dressing used for chronic wounds, improving its therapeutic efficacy.
  • This product can fill the urgent need for new medications that can cure ulcers faster and with an accessible price compared to products currently on the market.
Chiara Gai, Chair, EvoBiotech
Thomas Meany
PITCH AND PARTNER
14:50

Reserved for OpenCell.bio

Thomas Meany, Director, OpenCell.bio
16:00

Networking refreshments

18:00

Close of conference

last published: 05/Mar/20 17:05